A non-exclusive collaboration between NanoCellect and QIAGEN aims to accelerate adoption and ease of use of single-cell RNAseq by combining the power of NanoCellect’s WOLF® Cell Sorter with QIAGEN’s QIAseq® UPX 3′ Transcriptome Kit
SAN DIEGO and GERMANTOWN, Md. and HILDEN, Germany, June 24, 2019/PRNewswire/ — QIAGEN N.V. and NanoCellect Biomedical, Inc., a leader in cell analysis and sorting technology, announced today a scientific collaboration to improve the cell sample prep upstream of QIAGEN’s QIAseq® UPX 3′ Transcriptome Kit through the utilization of NanoCellect’s WOLF Cell Sorter technology, which allows for individual cells to be gently sorted into RNAseq- ready 96-well plates.
Single-cell RNA-seq analysis focuses on the individual contribution of every cell, highlighting a specific biological response otherwise obscured when assessed in bulk. The greatest bottleneck to single-cell analysis is the lack of easy-to-use methods for precisely isolating single cells from a heterogeneous cell population and debris, without damaging the cells, and dispensing them into 96- or 384-well plates. Combining the power of NanoCellect’s WOLF Cell Sorter with QIAGEN’s QIAseq UPX 3′ Transcriptome Kit provides a high-tech, synergistic Sample to Insight® workflow solution.
The two parties are working together to optimize a solution that simplifies the workflow and accessibility to precisely aliquot single (or up to 100) of cells per well. Customers will be able to leverage the dispensed cells with the high-performance and sensitivity of the QIAseq UPX 3′ kits and thereby achieve the goal of enabling high-throughput 3′ transcriptome NGS from ultralow amounts of RNA. The combination of cell IDs and sample IDs enables up to 18,432 libraries to be sequenced together, providing users with an innovative solution to many NGS challenges.
Click here to read the entire Press Release.